International Journal of Hematology and Oncology 2023, Vol 33, Num 4 Page(s): 008-012
HYPERFACTIONED RADIOTHERAPY IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER

SEMA DURMUS1, ALİ RIZA ÜÇER1, TAMER ÇALIKOĞLU1, FAİK ÇETİNDAĞ1, OSMAN N. SUNTER1, MUZAFFER ALTUNDAĞ1

Sağlık Bakanlığı, Ankara Onkoloji Hastanesi Radyasyon Onkolojisi Kliniği, ANKARA

Keywords: lung cancer, hyperfraction, radiotherapy
Between December 1994 and September 1995 21 non-small cell lung cancer (NSCLC) patients with good performance status (Karnofsky >60 and loss of weight <%10 of body weight) treated with twice daily fractions of 120 cGy to a total dose of 6480 cGy. We observed 23.5% complete and 41.2% partial response rates. There were 23.8% acute lung toxicity rate One year and two-year overall survival rates were %52 and %16 respectively. The mean survival was 17 months. Hyperfractioned radiotherapy may be acceptable treatment modality in NSCLC patients who have good performance status.